Bionanoparticle‐Based Delivery in Antihypertensive Vaccine Mediates DC Activation through Lipid‐Raft Reorganization
Source abstract
Abstract
Abstract Bionanoparticles (BNPs) are widely used as vaccine carriers. Compared with classic protein carriers, BNPs exhibit nanostructures that enable them to interaction with biointerface‐like cell membrane or membrane domains. An antihypertensive vaccine ATR‐NP is produced based on a virus‐like particle (VLP) Qβ carrier. Qβ shows great delivery efficiency and immunogenicity to antigen‐presenting cells (APCs) such as dendritic cells (DCs), and DC activation induced by ATR‐NP is highly dependent on membrane lipid rafts. Further studies reveal that ATR‐NP exhibits tight affinity to rafts, and interface effects between them prompt membrane phase separation and raft accumulation through NP‐induced membrane curvature change. Lipid rafts are accumulated and expanded together with a decline of their diffusion in membrane, which benefits signaling protein Src partition in rafts. The heterogeneous protein partition implies functional centralization for stronger signal transduction. In conclusion, targeting and reorganizing membrane domains such as lipid rafts suggests BNPs could be used as vaccine carriers and is a potent strategy for vaccine and other immunological agent design.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Lipid Membrane Structure and Behavior · Influenza Virus Research Studies · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Cardiology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China
National Center for Nanoscience and Technology Beijing 100190 China
Key Laboratory of Molecular Nanostructure and Nanotechnology Institute of Chemistry, Chinese Academy of Science Beijing 100190 China
Funding
National Natural Science Foundation of China · Young Scientists Fund
References (53)
Show source-provided references
1. 10.1016/S0140-6736(05)17741-110.1016/S0140-6736(05)17741-1 ↗
2. 10.1016/S0140-6736(18)32225-610.1016/S0140-6736(18)32225-6 ↗
3. 10.1161/CIRCULATIONAHA.115.01891210.1161/CIRCULATIONAHA.115.018912 ↗
4. 10.1098/rstb.2011.010310.1098/rstb.2011.0103 ↗
5. 10.1161/HYPERTENSIONAHA.112.20102010.1161/HYPERTENSIONAHA.112.201020 ↗
6. 10.1161/CIRCRESAHA.116.30358710.1161/CIRCRESAHA.116.303587 ↗
7. 10.1002/adhm.20120026810.1002/adhm.201200268 ↗
8. 10.1002/emmm.20140387610.1002/emmm.201403876 ↗
9. 10.1038/nmat505710.1038/nmat5057 ↗
10. 10.1126/science.824878410.1126/science.8248784 ↗
11. 10.1021/nn800827310.1021/nn8008273 ↗
12. 10.1007/s00018-018-2765-410.1007/s00018-018-2765-4 ↗
13. 10.1038/4240810.1038/42408 ↗
14. 10.1073/pnas.223562010010.1073/pnas.2235620100 ↗
15. 10.1111/j.1747-0285.2005.00319.x10.1111/j.1747-0285.2005.00319.x ↗
16. 10.1016/j.rvsc.2017.04.00910.1016/j.rvsc.2017.04.009 ↗
17. 10.1039/C5EN00098J10.1039/C5EN00098J ↗
18. Chakraborty A. · Chem. Lett. · 2015 · 6 · 3688
19. 10.1073/pnas.170252611410.1073/pnas.1702526114 ↗
20. 10.1080/09168451.2017.128907410.1080/09168451.2017.1289074 ↗
21. 10.1196/annals.1391.02710.1196/annals.1391.027 ↗
22. 10.1002/smll.20160105310.1002/smll.201601053 ↗
23. 10.1038/nbt133210.1038/nbt1332 ↗
24. 10.1038/ni.355410.1038/ni.3554 ↗
25. 10.3390/vaccines402001510.3390/vaccines4020015 ↗
26. 10.1038/ncb165710.1038/ncb1657 ↗
27. 10.1038/nri219310.1038/nri2193 ↗
28. 10.1021/jacs.6b0554010.1021/jacs.6b05540 ↗
29. 10.1016/j.bpj.2010.04.04410.1016/j.bpj.2010.04.044 ↗
30. 10.1016/j.colsurfb.2013.12.04910.1016/j.colsurfb.2013.12.049 ↗
31. 10.1002/pros.2059310.1002/pros.20593 ↗
32. 10.1083/jcb.20030910110.1083/jcb.200309101 ↗
33. 10.1140/epje/i2013-13074-310.1140/epje/i2013-13074-3 ↗
34. 10.1038/ncomms227310.1038/ncomms2273 ↗
35. 10.1016/j.bbamem.2016.01.02210.1016/j.bbamem.2016.01.022 ↗
36. 10.1039/C3SM52522H10.1039/C3SM52522H ↗
37. 10.1529/biophysj.106.09792310.1529/biophysj.106.097923 ↗
38. 10.1016/S0001-8686(99)00016-010.1016/S0001-8686(99)00016-0 ↗
39. 10.1103/PhysRevE.62.526310.1103/PhysRevE.62.5263 ↗
40. 10.1021/la101263210.1021/la1012632 ↗
41. 10.1073/pnas.111634410810.1073/pnas.1116344108 ↗
42. 10.1039/C7NR03926C10.1039/C7NR03926C ↗
43. 10.1016/j.celrep.2013.08.02410.1016/j.celrep.2013.08.024 ↗
44. 10.1074/jbc.M21140220010.1074/jbc.M211402200 ↗
45. 10.1038/s41467-018-04164-110.1038/s41467-018-04164-1 ↗
46. 10.1073/pnas.101618410710.1073/pnas.1016184107 ↗
47. 10.1016/j.molimm.2004.04.01010.1016/j.molimm.2004.04.010 ↗
48. 10.1101/cshperspect.a00235210.1101/cshperspect.a002352 ↗
49. 10.1189/jlb.2A0815-344RR10.1189/jlb.2A0815-344RR ↗
50. 10.3389/fphar.2018.0033210.3389/fphar.2018.00332 ↗
51. 10.1158/0008-5472.CAN-06-453910.1158/0008-5472.CAN-06-4539 ↗
52. 10.1021/jp710302j10.1021/jp710302j ↗
53. 10.1016/j.bbrc.2007.02.08010.1016/j.bbrc.2007.02.080 ↗